Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vifor

Blood plasma giant's share price revives on growth path

An Aussie healthcare giant that put up its first annual loss as a listed group has staged a strong share price rebound as investors bet that the worst is over.

AAP · Aug 18

Aussie healthcare giant's shares plunge to decade-low

Some $10 billion has been wiped from the market capitalisation of blood products manufacturer CSL after a dismal announcement.

AAP · May 11

Vifor Pharma to pay £23m to NHS after competition probe into misleading claims

The competition watchdog was investigating whether the drugs firm had been spreading misleading information on a rival’s treatment.

The Independent UK · Dec 10, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Angion Biomedica Is 'Better Positioned' Than Peers Despite Trial Failure, HC Wainwright Thinks So

HC Wainwright has removed Angion Biomedica Corp's (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating. In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data. The analyst…

Benzinga · Apr 18, 2022

FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff

Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc (NASDAQ:AKBA) has layoffs that are now on the way. In a filing with the SEC, Akebia said the FDA issued a partial clinical hold on the drug's pediatric studies. As a result, Akebia will suspend all vadadustat studies…

Benzinga · Apr 7, 2022

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study

Benzinga · Feb 23, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

United States

425,047 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.